Chinese PLA General Hospital

Running trials

• Recruiting

  Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy

  NCT07789184· Phase 3· Hua Huang, MD, PhD· Source

• Not yet recruiting

  BCMA/GPRC5D Dual-Target CAR-T Cell Immunotherapy for Relapsed/Refractory Multiple Myeloma

  NCT07927842· Phase 1· Liping Dou· Source

• Not yet recruiting

  CLL-1/CD70 Dual-Target CAR-T Cell Therapy for Acute Myeloid Leukemia

  NCT07897136· Phase 1· Liping Dou· Source

• Not yet recruiting

  A Phase 3 Study of Deutenzalutamide in Patients With High-Risk BCR Prostate Cancer

  NCT07875881· Phase 3· Hinova Pharmaceuticals Inc.· Source

• Not yet recruiting

  A Single-Arm, Phase II Study of Retlirafusp Alfa in Combination With XELOX and Bevacizumab for the First-Line Treatment of Advanced RAS-Mutated Colorectal Cancer With Liver Metastases (CRLM)

  NCT07797244· Phase 2· Dai, Guanghai· Source

• Not yet recruiting

  Clinical Trial of SEEG for Drug-resistant Epilepsy

  NCT07923058· Beijing Pins Medical Co., Ltd· Source

• Not yet recruiting

  CLL-1-Targeted In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory Acute Myeloid Leukemia

  NCT07841002· Phase 1· Liping Dou· Source

• Not yet recruiting

  PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke

  NCT07466251· Phase 4· Peking Union Medical College Hospital· Source

• Recruiting

  CD19 Sequential CD22 In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

  NCT07927816· Phase 1· Liping Dou· Source

• Recruiting

  Obinutuzumab Beta Combined With Low-dose Glucocorticoid in New-onset ANCA-Associated Glomerulonephritis

  NCT07746180· Phase 2· Chinese PLA General Hospital· Source

• Not yet recruiting

  Luvometinib in Combination With Serplulimab for NF2-Related Tumors

  NCT07708285· Phase 1/2· Beijing Tiantan Hospital· Source

• Active, not recruiting

  Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

  NCT07651475· Phase 2· Liping Dou· Source

• Not yet recruiting

  Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)

  NCT07713745· Phase 2· Beijing Tiantan Hospital· Source

• Not yet recruiting

  Clinical Study on the Efficacy and Safety of Nalfurafine Hydrochloride Orally Disintegrating Tablets in Treating Pruritus in Patients Undergoing Maintenance Hemodialysis

  NCT07650851· Chinese PLA General Hospital· Source

• Recruiting

  Cold-Region Exposure and Cardiac Remodeling After PCI

  NCT07773870· Chinese PLA General Hospital· Source

• Not yet recruiting

  Chinese, Overweight or Obesity, Real-World Registry Study

  NCT07525037· Chinese PLA General Hospital· Source

• Recruiting

  Effect of the Traditional Chinese Medicine Yufeng Ningxin in Patients With Hypertension

  NCT07607275· Phase 4· Beijing Anzhen Hospital· Source

• Not yet recruiting

  The Safety and Efficacy of KSVCBD Injection in Neuromyelitis Optica Spectrum Disorder.

  NCT07592754· Early phase 1· Chinese PLA General Hospital· Source

• Recruiting

  A Phase I Study of [18F]Flortaucipir PET Imaging in Chinese Subjects: Safety, Pharmacokinetics, Biodistribution, Radiation Dosimetry, and Preliminary Diagnostic Efficacy

  NCT07580703· Phase 1· Eli Radiopharma· Source

• Not yet recruiting

  Predictive Role of Photon Counting Computed Tomography in Acute Coronary Syndrom Patients

  NCT07536607· Chinese PLA General Hospital· Source

• Recruiting

  VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial

  NCT07514832· Phase 2· Beijing 302 Hospital· Source

• Recruiting

  Multicenter Validation of the 2025 Classification Criteria for Axial Spondyloarthritis

  NCT07724847· Chinese PLA General Hospital· Source

• Not yet recruiting

  Chronic Kidney Disease and Metabolic Disorders in the Elderly

  NCT07494526· Chinese PLA General Hospital· Source

• Recruiting

  A Study of HDM1005 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone

  NCT07394114· Phase 3· Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.· Source

• Enrolling by invitation

  Anesthetic Management Guided by the Medstrom Instrument

  NCT07089017· Chinese PLA General Hospital· Source

• Not yet recruiting

  Development and Validation of a Cardiac Magnetic Resonance-Based Multimodal Deep Learning Model for Long-Term Outcome Prediction in ST-Segment Elevation Myocardial Infarction

  NCT07277400· Qian geng· Source

• Enrolling by invitation

  Development and Validation of a Non-Invasive AI Diagnostic Model for Prostate Cancer Using Multiparametric MRI and PSMA PET/CT

  NCT07690306· Xiangya Hospital of Central South University· Source

• Recruiting

  Photon-counting CT for Intracranial Stent Assessment

  NCT07769814· Xin Lou· Source

• Not yet recruiting

  Urinary Function and Multimorbidity Risks: A Longitudinal Study in Beijing Community-Dwelling Elderly

  NCT07357714· Chinese PLA General Hospital· Source

• Recruiting

  CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma

  NCT07587840· Phase 2· Liping Dou· Source

• Recruiting

  Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL

  NCT07575919· Phase 1/2· Liping Dou· Source

• Recruiting

  Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia

  NCT07575971· Phase 1/2· Liping Dou· Source

• Recruiting

  Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer

  NCT07392346· Phase 2· Dai, Guanghai· Source

• Recruiting

  IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

  NCT07198841· Phase 2· Guangdong Association of Clinical Trials· Source

• Recruiting

  Letermovir Prophylaxis Duration Guided by CMV-Specific T-cell Monitoring After Allo-HSCT.

  NCT07569653· Phase 4· WeiShi· Source

• Recruiting

  Haplo-Cord HSCT for AML/MDS

  NCT07588360· Fujian Medical University Union Hospital· Source

• Recruiting

  Early Application of Budesonide Enteric-coated Capsules in the Treatment of Primary IgA Nephropathy.

  NCT07585981· Chinese PLA General Hospital· Source

• Recruiting

  Exploratory Study of Personalized mRNA Vaccine in Patients With Refractory Rhabdomyosarcoma

  NCT06932861· Early phase 1· Xinxin Zhang· Source

• Recruiting

  Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction

  NCT07489534· Phase 2· Daihong Liu· Source

• Recruiting

  Venetoclax Combined With CACAG Regimen Versus "3+7" Regimen in the Treatment of Acute Monocytic Leukemia

  NCT07512700· Phase 2· Chinese PLA General Hospital· Source

• Recruiting

  Polymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/Leukemia

  NCT07321301· Phase 2· Daihong Liu· Source

• Recruiting

  Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

  NCT07165886· Phase 2/3· CSPC ZhongQi Pharmaceutical Technology Co., Ltd.· Source

• Recruiting

  A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients

  NCT07103668· Phase 3· Suzhou Immunofoco Biotechnology Co., Ltd· Source

• Recruiting

  Pegmolesatide Treatment for Anemia in Patients Undergoing Long-term Dialysis

  NCT07045155· Phase 4· Chinese PLA General Hospital· Source

• Recruiting

  Alzheimer's Disease Multinuclear Imaging Neuro-Enhanced Resolution (AD-MINER)

  NCT07089303· Chinese PLA General Hospital· Source

• Recruiting

  VIM+PTT MRgFUS for PD

  NCT07044973· Chinese PLA General Hospital· Source

• Recruiting

  Clinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma

  NCT07067905· Early phase 1· Chinese PLA General Hospital· Source

• Recruiting

  Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease

  NCT06969807· Phase 2· Chinese PLA General Hospital· Source

• Active, not recruiting

  Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation

  NCT07094464· Phase 1· Daihong Liu· Source

• Recruiting

  Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.

  NCT07489989· Phase 2· Daihong Liu· Source

Showing 50 of 149.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Liver and biliary tract cancer16 recruiting
• Childhood cancers15 recruiting
• Acute myeloid leukaemia11 recruiting
• Chronic kidney disease11 recruiting
• Alzheimer disease7 recruiting
• Colorectal cancer7 recruiting
• Gastric and oesophageal cancer7 recruiting
• Acute lymphoblastic leukaemia6 recruiting
• Coronary artery disease5 recruiting
• Lung cancer4 recruiting
• Stroke4 recruiting
• Prostate cancer3 recruiting
• Thyroid cancer3 recruiting
• Type 2 diabetes3 recruiting
• Ankylosing spondylitis2 recruiting
• Aortic aneurysm2 recruiting
• Glioblastoma2 recruiting
• High blood pressure2 recruiting
• Meningioma2 recruiting
• Multiple myeloma2 recruiting
• Myelodysplastic syndromes2 recruiting
• Neuroendocrine tumours2 recruiting
• Pancreatic cancer2 recruiting
• Parkinson disease2 recruiting
• Vascular dementia2 recruiting
• ANCA-associated vasculitis1 recruiting
• Cytomegalovirus infection1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Dystonia1 recruiting
• Epilepsy1 recruiting
• Essential tremor1 recruiting
• Follicular lymphoma1 recruiting
• Graves' disease and hyperthyroidism1 recruiting
• Hodgkin lymphoma1 recruiting
• IgA nephropathy1 recruiting
• Kidney cancer1 recruiting
• Neuromyelitis optica (NMOSD)1 recruiting
• Obesity1 recruiting
• Pompe disease1 recruiting
• Sarcoma1 recruiting

Closed trials

• Completed

  A Clinical Trial Evaluating the Safety and Tolerability, Biodistribution and Radiation Dosimetry, and Pharmacokinetics of Flotufolastat F-18 Injection in Healthy Chinese Adults

  NCT07149831· Phase 1· Sinotau Pharmaceutical Group· Source

• Completed

  A Trial of HRS-7535 Tablets in Subjects With Overweight or Obesity

  NCT06904105· Phase 3· Shandong Suncadia Medicine Co., Ltd.· Source

• Completed

  Diagnostic Efficacy and Safety of Flotufolastat F-18 Injection in Subjects With Biochemical Recurrence of Prostate Cancer

  NCT07115277· Sinotau Pharmaceutical Group· Source

• Completed

  Different Cycles of Neoadjuvant PD-1 Blockades + Chemotherapy for Advanced Gastric Cancer

  NCT06798376· Chinese PLA General Hospital· Source

• Completed

  Long-term Efficacy and Safety of HRS-7535 Tablets in Obese Subjects

  NCT06671821· Phase 2· Shandong Suncadia Medicine Co., Ltd.· Source

• Completed

  Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine

  NCT06241313· Phase 3· AbbVie· Source

• Withdrawn

  Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune Thrombocytopenia

  NCT06176235· Phase 2· Peking University People's Hospital· Source

• Completed

  A Phase I Clinical Study on the Safety and Pharmacokinetics of [18F]Florbetazine Injection

  NCT06593626· Phase 1· HTA Co., Ltd.· Source

• Completed

  Microvascular Invasion Artificial Intelligence Prediction Via Contrast-enhanced Ultrasound With Explainability

  NCT06760494· Chinese PLA General Hospital· Source

• Completed

  A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)

  NCT05963022· Phase 3· Eli Lilly and Company· Source

• Completed

  Henagliflozin Reducing Infarct Size After Priamry PCI in Patients With ST Segment Elevation Myocardial Infarction

  NCT06187727· Phase 4· Qian geng· Source

• Completed

  A Study to Evaluate XTR006 in Chinese Volunteers

  NCT06151795· Phase 1· Sinotau Pharmaceutical Group· Source

• Completed

  A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

  NCT05872620· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.

  NCT05810038· Phase 3· Pfizer· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia

  NCT06068621· Phase 2· Chinese PLA General Hospital· Source

• Completed

  A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease

  NCT05529992· Phase 3· Takeda· Source

• Completed

  Clinical Study of Venetoclax Combined with CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia

  NCT05659992· Phase 2· Chinese PLA General Hospital· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Boehringer Ingelheim· Source

• Completed

  Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer

  NCT05509699· Phase 2· Hutchison Medipharma Limited· Source

• Completed

  Analysis of XTR006 PET Imaging in Non-cognitively Impaired Subjects, MCI Due toAD, and Mild to Moderate AD Subjects

  NCT06151808· Sinotau Pharmaceutical Group· Source

• Completed

  A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM

  NCT05918107· Phase 2· Biotheus Inc.· Source

• Terminated

  A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors

  NCT05427396· Phase 1· Shanghai Junshi Bioscience Co., Ltd.· Source

• Completed

  Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and Chemotherapy

  NCT06202781· Chinese PLA General Hospital· Source

• Completed

  A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants

  NCT05371652· Phase 3· Pfizer· Source

• Terminated

  GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma

  NCT05352542· Phase 1· jianming xu· Source

• Completed

  Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy

  NCT05323734· Phase 3· Marinus Pharmaceuticals· Source

• Completed

  A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors

  NCT05173142· Phase 1/2· Hutchison Medipharma Limited· Source

• Completed

  Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD

  NCT05003245· Phase 3· Shanghai Henlius Biotech· Source

• Completed

  CEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal Adenocarcinoma

  NCT05052567· Phase 1/2· Qilu Pharmaceutical Co., Ltd.· Source

• Completed

  A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease

  NCT05047263· Phase 3· Bayer· Source

• Completed

  GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer

  NCT05054751· Phase 3· Genor Biopharma Co., Ltd.· Source

• Completed

  GSL Synthetase Inhibitor in Combination With Immune Checkpoint Inhibitor in Previously Treated Blood and Solid Tumor

  NCT04944888· Phase 1· Chinese PLA General Hospital· Source

• Completed

  Efficacy and Safety of SHR-1314 in Patients With Active Ankylosing Spondylitis

  NCT04840485· Phase 2/3· Suzhou Suncadia Biopharmaceuticals Co., Ltd.· Source

• Completed

  EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

  NCT04509674· Phase 3· Boehringer Ingelheim· Source

• Completed

  Evaluate the Effect of Injectable Neucardin on the Cardiac Function of Subjects With Chronic Systolic Heart Failure

  NCT04468529· Phase 3· Zensun Sci. & Tech. Co., Ltd.· Source

• Completed

  Effect of Long Term Trimetazidine Treatment on Final Myocardial Fibrosis for ST Eleviation Myocardial Infarction

  NCT07325955· Chinese PLA General Hospital· Source

• Completed

  A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma

  NCT04444167· Phase 1/2· Akeso· Source

• Completed

  A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

  NCT04102020· Phase 3· AbbVie· Source

• Completed

  A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations

  NCT04083976· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

  NCT04005716· Phase 3· BeiGene· Source

• Completed

  A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata

  NCT03899259· Phase 3· Eli Lilly and Company· Source

• Completed

  NeuWave Microwave Ablation HCC China Study

  NCT03783871· Ethicon, Inc.· Source

• Completed

  Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

  NCT03734029· Phase 3· Daiichi Sankyo· Source

• Completed

  Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment

  NCT04085276· Phase 3· Shanghai Junshi Bioscience Co., Ltd.· Source

• Completed

  Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

  NCT03777657· Phase 3· BeiGene· Source

• Terminated

  A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer

  NCT03866980· Phase 3· Akeso· Source

• Completed

  A Prospective Multicenter Clinical Study on the Long-term Prognosis of Patients With ST-segment Elevation Myocardial Infarction Using Cardiac Magnetic Resonance Imaging.

  NCT07057492· Chinese PLA General Hospital· Source

• Completed

  A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)

  NCT03412773· Phase 3· BeiGene· Source

• Completed

  Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)

  NCT03358875· Phase 3· BeiGene· Source

Showing 50 of 53.

Conditions

Diseases this institution publishes on or runs trials for.

• Liver and biliary tract cancer186 works · 23 trials
• Lung cancer129 works · 11 trials
• Stroke125 works · 5 trials
• Gastric and oesophageal cancer77 works · 14 trials
• Colorectal cancer73 works · 8 trials
• Chronic kidney disease70 works · 13 trials
• Hearing loss63 works · 0 trials
• Osteoarthritis53 works · 0 trials
• Kidney cancer49 works · 1 trial
• Prostate cancer48 works · 5 trials
• Tuberculosis44 works · 0 trials
• Osteoporosis39 works · 0 trials
• Migraine36 works · 6 trials
• Coronary artery disease34 works · 12 trials
• Hepatitis B32 works · 0 trials
• Bladder cancer28 works · 1 trial
• Glioblastoma27 works · 2 trials
• COPD26 works · 0 trials
• Acute myeloid leukaemia21 works · 17 trials
• Spinal cord injury16 works · 0 trials
• Thyroid cancer16 works · 3 trials
• ALS (motor neurone disease)15 works · 0 trials
• Aortic aneurysm12 works · 2 trials
• Liver cirrhosis12 works · 0 trials
• Ankylosing spondylitis11 works · 3 trials
• IgA nephropathy9 works · 1 trial
• Myelodysplastic syndromes9 works · 3 trials
• Hypothyroidism8 works · 0 trials
• Hydrocephalus7 works · 0 trials
• Pompe disease6 works · 1 trial